AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claim 1. (currently amended): An ω-naphthyloxy amino alkane ~~derivatives~~ compound having structural formula I,



I

~~Wherein~~ wherein R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon ~~atomsselected~~ atoms selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl and hexyl; a branched chain lower alkyl selected from the group consisting of isopropyl, isobutyl, t-butyl and alkyl chains thereof; a cyclic alkane selected from the group consisting of cyclopropyl, cyclobutyl, cyclohexyl, cycloheptyl and cyclic alkanes thereof; a lower alkoxy in which the alkyl group is as mentioned above, n is 1 to 6; R_3 and R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined above; an aryl residue selected from the group consisting of phenyl and naphthyl; an arylalkyl residue selected from the ~~groupconsisting~~ group consisting of benzyl and substituted benzyl, form a part of a heterocylic ring selected from the group consisting of pyrrolidine and piperidine, form a heterocylic ring with additional heteroatoms ~~O,N,S~~O, N, S selected from the group consisting of piperazine, morpholine, oxazole, ~~oxathinazole~~ oxathiazole and oxathiazine; an alkoxy carbonyl alkane represented by the formula R_6COOR_7, wherein R_6 is

$(CH_2)n$ (n=1-3) and R_7 is a lower alkyl as defined above, provided that either R_1 and R_2 or R_3 and R_4 are not both H.

Claim 2. (currently amended): The ω-naphthyloxy amino alkane ~~derivatives~~ compound as claimed in claim ~~1selected~~ 1, selected from the group consisting of:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]amine [I:_R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl] amine [I: R_1= R_2=H, R_3= propyl R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino**[[}]]** acetic acid ethyl ester [I: R_1=R_2=H, R_3=CH_2COOEt,R_4=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine__[I:__R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)butylamine [I:_R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]_amine_[I:_R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:__R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]_amine_[I:_R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]_amine_[I:_R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine_[I:_R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]___amine___[I:___R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]__amine [I:__R_1=R_2=R_3=__H, __R_4~~H,R~~$_4$= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:_R_1=R_2=R_3=H,R_4= benzyl, n=3] **[[]]]**

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]__amine__[I:__R_1=R_2=R_3=H,R_4= benzyl, n=4] **[[]]]**

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]_amine_[I: **[[:]]** R_1 = R_2 = R_3 = H, R_4 = ~~cylohexyl~~cyclohexyl, n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4 = ~~cylohexyl,n=3~~cyclohexyl, n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]__amine__[I:__R_1=R_2=R_3=H, R_4 = ~~cylohexyl,n=4~~cyclohexyl, n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]_amine [I: **[[:]]** R_1 = R_2 = R_3 = ~~H,R~~$_4$H, R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine_[I:_R_1=R_2= R_3= H, R_4=2-ethyl- n-hexyl, n=3]**[[.]]**

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl] amine___[I:___R_1=R_2=R_3=H, **[[,]]**R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]_amine [I:_R_1=R_2=R_3= H, R_4~~H,R_4~~= ~~n-dodecyl,n=2~~n-dodecyl, n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:_R_1= R_2 = R_3 = H, R_4=~~n-dodecyl,n=3~~n-dodecyl, n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]_amine_[I:_R_1=R_2= R_3= H, R_4~~H,R_4~~= ~~n-dodecyl,n=4~~n-dodecyl, n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]_amine [I:_R_1=R_2 = R_3 = H, R_4~~H,R_4~~= isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]__amine__[I:__R_1=R_2=R_3=H R_4 = isoamyl, n =3]

(xxviii) N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]_amine_[I: **[[:]]** R_1 = R_2 = R_3 = H, **[[,]]** R_4 = ~~isoamyl,n=4~~isoamyl, n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:_R_1=R_2= R_3=H, **[[,]]** R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1=R_2=R_3= H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=2]

(xxxiii) N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]_amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=3]

(xxxiv) N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-butyl, n=4]

(xxxvi) N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I:**[[,]]** R_1=R_2=R_3=H, R_4=2-phenyl–ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I:**[[,]]** R_1=R_2=R_3=H, R_4= Piperidinyl, n=4]

(xxxix) N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2= R_3= H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2= R_3= H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]_amine [I:**[[,]]** R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propyl]_amine [I:**[[,]]** R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4 Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl]__amine [I:**[[,]]** R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]**R_1=R_2=H, R_3= n-butyl, R_4=4-methoxyphenyl~~4-Methoxyphenyl~~, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino**[[}]]** acetic acid ethyl ester[I:**[[,]]** R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-methoxyphenyl~~4-Methoxyphenyl~~, n=3]

(xlviii) 2,7-Bis[3-(4-methoxyphenylamino)propyloxy]____naphthalene____[I:**[[,]]**R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

and

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I:**[[,]]**R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl].

Claim 3. (currently amended): The ω-naphthyloxy amino alkane compound ~~Derivatives~~ as claimed in claim 1, wherein said ~~derivatives are~~compound is useful for treatment ~~and prevention~~ of hyperglycemia and cardiovascular disorders (CVS) in mammals, including humans.

Claim 4. (currently amended): The ω-naphthyloxy amino alkane compound ~~Derivatives~~ as claimed in claim 1, wherein the said ~~derivatives~~ compound ~~can be~~ is administered

as a pharmaceutical composition optionally along with a pharmaceutically acceptable ~~salt/s~~salt, ~~carrier/s~~carrier or ~~dilutent/s~~diluent.

Claim 5. (currently amended): The ω-naphthyloxy amino alkane compound ~~Derivatives~~ as claimed in claim 4, wherein the ~~salts/carriers/diluents are~~salt, carrier or diluent is selected from the a group ~~comprising~~ consisting of lactose, sodium chloride, potassium chloride, magnesium sulphate, magnesium chloride, potassium sulfate, sodium sulfate, lithium sulphate, sodium phosphate, potassium phosphate, magnesium succinate, sodium carbonate, sodium sulfate, potassium acid phosphate ~~or~~ and calcium bicarbonate.

Claim 6. (currently amended): The ω-naphthyloxy amino alkane compound ~~Derivatives~~ as claimed in claim 1 wherein the dosage of the said ~~derivatives~~ compound is in the range of about 250-350 μmol/Kg.**[[,]]**

Claim 7. (currently amended): The ω-naphthyloxy amino alkane ~~Derivatives~~ as claimed in claim 6 wherein, the dosage of the said ~~derivatives~~ compound is ~~preferably~~ about 300 μmol/Kg.

Claim 8. (currently amended): The ω-naphthyloxy amino alkane compound ~~Derivatives~~ as claimed in claim 1, wherein said ~~derivatives may be~~compound is administered in the form of a syrup, a capsule, a tablet, an intravenous preparation, a liquid or a suspension.

Claim 9. (currently amended): The ω-naphthyloxy amino alkane compound~~Derivatives~~ as claimed in claim 1, wherein the compound is administered orally, intranasally, rectally, or parenterally~~method of administration for said derivatives may be oral, nasal, rectoral, or parenteral~~.

Claim 10. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 1, wherein said ~~derivatives~~ compound ~~lower~~lowers ~~the~~ plasma concentration of cholesterol by about 30%.

Claim 11. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 10, wherein said ~~derivatives~~ compound ~~lower~~ lowers ~~the~~ plasma concentration of cholesterol by about 26%.

Claim 12. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in ~~claims~~ claim 1 wherein said ~~derivatives~~ compound ~~lower~~ lowers ~~the~~ plasma concentration of ~~phospholipid~~ phospholipids by about 35 %.

Claim 13. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 12, wherein said ~~derivatives~~ compound ~~lower~~ lowers ~~the~~ plasma concentration of ~~phospholipid~~phospholipids by about 30%.

Claim 14. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 1 wherein said ~~derivatives~~ compound ~~lower~~ lowers ~~the~~ plasma concentration of ~~Triglyceride~~ triglycerides by about 50 %.

Claim 15. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 14 wherein said ~~derivatives~~ compound ~~lower~~ lowers ~~the~~ plasma concentration of ~~Triglyceride~~ triglycerides by about 48%.

Claim 16. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 1 wherein said ~~derivatives~~ compound ~~enhance~~ enhances ~~the~~ plasma concentration of high-density ~~lipoprotein~~ lipoproteins (HDL) by about 20 %.

Claim 17. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 16 wherein said ~~derivatives~~ compound ~~enhance~~ enhances ~~the~~ plasma concentration of high-density ~~lipoprotein~~ lipoproteins (HDL) by about 15%.

Claim 18. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 1 wherein said ~~derivatives~~ compound lowers ~~the~~ plasma glucose (GLU) concentration by about 35 %.

Claim 19. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 18 wherein said ~~derivatives~~ compound ~~lower~~lowers ~~the~~ plasma glucose concentration by about 30%.

Claim 20. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 1 wherein said ~~derivatives~~ compound lowers ~~the~~ plasma glycerol (GLY) concentration by about 20 %.

Claim 21. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 1 wherein said ~~derivatives~~ compound lowers ~~the~~ plasma glycerol (GLY) concentration by about 14 %.

Claim 22. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 1 wherein said ~~derivatives~~ compound ~~lower~~lowers ~~the~~ plasma glucose concentration in about 30 min to 10 hours ~~during~~ post ~~drug~~ administration.

Claim 23. (currently amended): ~~Derivatives~~ The ω-naphthyloxy amino alkane compound as claimed in claim 22 wherein, the compound~~derivatives~~ ~~lower~~lowers ~~the~~ plasma glucose concentration in about 1 hr to 7 hrs ~~during~~ post ~~drug~~ administration.

Claim 24. (currently amended): A method for preparing an ω-naphthyloxy amino alkane ~~derivatives~~ compound having structural formula I,



I

~~Wherein~~ wherein R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon ~~atomsselected~~ atoms selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl

and hexyl; a branched chain lower alkyl selected from the group consisting of isopropyl, isobutyl and t-butyl; a cyclic alkane selected from the group consisting of cyclopropyl, cyclobutyl, cyclohexyl and cycloheptyl; a lower alkoxy in which the alkyl group is as mentioned above, n is 1 to 6; R_3 and R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined above; an aryl ~~residueselected~~ residue selected from the group consisting of phenyl~~, substituted phenyl~~ and naphthyl; an arylalkyl residue selected from the group consisting of benzyl and substituted benzyl, form a part of a heterocylic ring selected from the group consisting of pyrrolidine and piperidine, form a heterocylic ring with additional heteroatoms ~~O,N,S~~O, N, S selected from the group consisting of piperazine, morpholine, oxazole, ~~oxathinazole~~ oxathiazole and oxathiazine; an alkoxy carbonyl alkane represented by the formula R_6COOR_7, wherein R_6 is $(CH_2)n$ (n=1-3) and R_7 is a lower alkyl as defined above, said process comprising steps of:

(a) reacting a substituted β-naphthol of ~~Formula~~ formula II with a dihaloalkane of formula III in an organic solvent in the presence of a base to obtain an intermediate compound of formula IV,



~~Wherein~~ wherein R_1 and R_2 are defined as above and wherein X_1 and X_2 may be same or different halogens, and

(b) reacting a compound of formula IV with an amine of formula V in the presence of an acid binding agent optionally in an organic solvent to obtain a compound of formula I, wherein X_2 is a halogen and R_3 and R_4 are defined as above.

Claim 25. (currently amended): ~~A~~ The method as claimed in claim 24, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound is~~are~~ selected from the group consisting of:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]amine [I: $R_1=R_2=R_3=H$, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl] amine [I: $R_1=R_2=H$, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino**[[}]]** acetic acid ethyl ester [I: R_1=R_2=H, R_3= CH_2COOEt, R_4~~CH_2COOEt~~,R_4=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]_amine_[I:_R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)_butylamine [I:_R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]_amine_[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:__R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]_amine_[I:_R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]_amine_[I:_R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine_[I:_R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]___amine___[I:___R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]__amine [I:__R_1=R_2=R_3=H,R_4= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:__R_1=R_2=R_3=H,R_4= benzyl, n=3] **[[]]]**

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]__amine__[I:__R_1=R_2=R_3=H,R_4= benzyl, n=4]

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I: R_1 = R_2 = R_3 = H, R_4 = ~~cylohexyl~~cyclohexyl, n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4 = ~~cylohexyl,n=3~~cyclohexyl, n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]__amine__[I:__R_1=R_2=R_3=H, R_4 = ~~cylohexyl,n=4~~cyclohexyl, n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]_amine [I: **[[:]]** R_1 = R_2 = R_3 = ~~H,R4~~H, R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine_[I:_R_1=R_2= R_3= H, R_4=2-ethyl- n-hexyl, n=3]**[[.]]**

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl] amine___[I:___R_1=R_2=R_3=H, **[[,]]**R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]_amine [I:_R_1=R_2=R_3= ~~H,R4~~H, R_4= ~~n-dodecyl,n=2~~n-dodecyl, n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:_R_1= R_2 = R_3 = H, R_4= ~~n-dodecyl,n=3~~n-dodecyl, n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]_amine_[I:_R_1=R_2= R_3= H, R_4~~H,R4~~= ~~n-dodecyl,n=4~~n-dodecyl, n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]_amine [I:_R_1=R_2 = R_3 = H, R_4~~H,R4~~= isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]__amine__[I:__R_1=R_2=R_3=H, R_4 = isoamyl, n =3]

(xxviii) N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I: **[[:]]** R_1 = R_2 = R_3 = H , R_4 = ~~isoamyl,n=4~~isoamyl, n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:_R_1=R_2= R_3=H, **[[,]]** R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1=R_2=R_3= H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=2]

(xxxiii) N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]_amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=3]

(xxxiv) N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-butyl, n=4]

(xxxvi) N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I:**[[,]]** R_1=R_2=R_3=H, R_4=2-phenyl-ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I:**[[,]]** R_1=R_2=R_3=H, R_4= Piperidinyl, n=4]

(xxxix) N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2= R_3= H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2= R_3= H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]_amine [I:**[[,]]** R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propyl]amine, [I:**[[,]]** R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4 Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl] amine**[[.]]** [I:**[[,]]** R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]**R_1=R_2=H, R_3= n-butyl, R_4=4-methoxyphenyl~~4-Methoxyphenyl~~, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester[I:**[[,]]** R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-methoxyphenyl~~4-Methoxyphenyl~~, n=3]

(xlviii) 2,7-Bis[3-(4-methoxyphenylamino)propyloxy]___naphthalene___[I:**[[,]]** R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

and

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]___naphthalene___[I:**[[,]]** R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl].

Claim 26. (currently amended): ~~A~~ The method as claimed in claim 24, wherein the organic solvent in step (a) is selected from the group consisting of dry acetone, ethanol, methanol, dimethyl sulphoxide (DMSO), dimethylformamide (DMF), ~~Hexamethylphosphoric~~ hexamethylphosphoric triamide (HMPA) and acetonitrile.

Claim 27. (currently amended): ~~A~~ The method as claimed in claim 24, wherein the base in step (a) is selected from ~~a~~ the group consisting of cesium carbonate, potassium carbonate, sodium carbonate and lithium carbonate .

Claim 28. (currently amended): ~~A~~ The method as claimed in claim 24, wherein the organic solvent in step (b) is selected from the group consisting of dimethyl sulphoxide

(DMSO), dimethylformamide (DMF), hexamethylphosphoricHexamethylphosphoric triamide (HMPA) and acetonitrile.

Claim 29. (currently amended): A The method as claimed in claim 24, wherein the temperature in step (a) is in range of about 50°C to 100°C[[,]].

Claim 30. (currently amended): TheA method as claimed in claim 29, wherein the temperature is in the range of about 60°C to 80°C.

Claim 31. (currently amended): A The method as claimed in claim 24, wherein the temperature in step (b) in the range of about 120°C to 180°C.

Claim 32. (currently amended): A The method as claimed in claim 31, wherein the temperature is preferably in the range of about 130°C to 150°C.

Claim 33. (currently amended): A The method as claimed in claim 24, wherein the reaction time in steps (a) and (b) is in the range of about 4 hours to 13 hours.

Claim 34. (currently amended): A The method as claimed in claim 33, wherein the reaction time in steps (a) and (b) is in the range of about 5 hours to 12 hours.

Claim 35. (currently amended): ~~A~~ The method as claimed in claim 24, wherein the ~~derivatives~~ ω-naphthyloxy amino alkane compound of formula ~~(I)~~1 ~~have~~has a ~~their~~ melting ~~points~~ point in the range of about 75°C to 170°C.

Claim 36. (currently amended): ~~A~~ The method as claimed in claim 35, wherein the ~~derivatives~~ ω-naphthyloxy amino alkane compound of formula ~~(I)~~1 ~~have~~ has a ~~their~~ melting ~~points~~ point in the range of about 78°C to 160°C.

Claim 37. (currently amended): ~~A~~ The method as claimed in claim 24, wherein the purity of ~~the~~ said ~~derivatives~~ ω-naphthyloxy amino alkane compound of formula ~~(I)~~I is in the range of about 80% to 100%.

Claim 38. (currently amended): ~~A~~ The method as claimed in claim 24, wherein the dosage of the said ω-naphthyloxy amino alkane compound~~derivatives~~ is in the range of about 250-350 μmol/Kg.

Claim 39. (currently amended): ~~A~~ The method as claimed in claim 38, wherein the dosage of the said ω-naphthyloxy amino alkane compound~~derivatives~~ is about 300 μmol/Kg.

Claim 40. (currently amended): ~~A~~ The method as claimed in claim 24, wherein the said ω-naphthyloxy amino alkane compound~~derivatives may be~~is administered in form of a syrup, a capsule, a tablet, a suspension or an intravenous preparation.

Claim 41. (currently amended): ~~A~~ The method as claimed in claim 40, wherein the ~~method of administration of said~~ ω-naphthyloxy amino alkane compound~~derivatives~~ is administered ~~oral, nasal, or parenteral~~orally, intranasally or parenterally.

Claim 42. (currently amended): ~~A~~ The method as claimed in claim 24, wherein said ω-naphthyloxy amino alkane compound~~derivatives~~ lower the plasma concentration ~~percentage of~~ cholesterol by about 30%.

Claim 43. (currently amended): ~~A~~ The method as claimed in claim 42, wherein said ω-naphthyloxy amino alkane compound~~derivatives~~ lowers the plasma concentration of cholesterol by about 26%.

Claim 44. (currently amended): ~~A~~ Thr method as claimed in claim 24, wherein said ω-naphthyloxy amino alkane compound~~derivatives lower~~ lowers the plasma concentration of ~~phospholipid~~ phospholipids by about 35 %.

Claim 45. (currently amended): ~~A~~ the method as claimed in claim 44, wherein said ω-naphthyloxy amino alkane compound~~derivatives lower~~ lowers the plasma concentration of ~~phospholipid~~ phospholipids by about 30%.

Claim 46. (currently amended): ~~A~~ The method as claimed in claim 24, wherein said ω-naphthyloxy amino alkane compound~~derivatives~~ ~~lower~~ lowers the plasma concentration of ~~triglyceride~~ triglycerides by about 50 %.

Claim 47. (currently amended): ~~A~~ The method as claimed in claim 46, wherein said ω-naphthyloxy amino alkane compound~~derivatives~~ ~~lower~~ lowers the plasma concentration of ~~triglyceride~~ triglycerides by about 48%.

Claim 48. (currently amended): ~~A~~ The method as claimed in claim 24, wherein said ω-naphthyloxy amino alkane compound~~derivatives~~ ~~enhance~~ enhances the plasma concentration of high-density ~~lipoprotein~~ lipoproteins (HDL) by about 20 %.

Claim 49. (currently amended): ~~A~~ The method as claimed in claim 48, wherein said ω-naphthyloxy amino alkane compound~~derivatives~~ ~~enhance~~ enhances the plasma concentration of high-density ~~lipoprotein~~ lipoproteins ~~preferably~~ by about 15%.

Claim 50. (currently amended): ~~A~~ The method as claimed in claim 24, wherein said ω-naphthyloxy amino alkane compound~~derivatives~~ ~~lower~~ lowers the plasma glucose (GLU) concentration by about 40 %.

Claim 51. (currently amended): ~~A~~ The method as claimed in claim 50, wherein said ω-naphthyloxy amino alkane compound~~derivatives lower~~ lowers the plasma glucose (GLU) concentration preferably by about 30 %.

Claim 52. (currently amended): ~~A~~ The method as claimed in claim 24 wherein said ω-naphthyloxy amino alkane compound~~derivatives lower~~ lowers the plasma glycerol (GLY) concentration by about 20 %.

Claim 53. (currently amended): ~~A~~ The method as claimed in claim 52 wherein, the dosage of the ω-naphthyloxy amino alkane compound~~derivatives~~ lowers the plasma glycerol concentration by about 14 %.

Claim 54. (currently amendedl): ~~A~~ The method as claimed in claim 24, wherein said ω-naphthyloxy amino alkane compound~~derivatives lower~~ lowers the plasma glucose concentration in about 30 min to 10 hours during post drug administration.

Claim 55. (currently amended): The~~A~~ method as claimed in claim 54, wherein said ω-naphthyloxy amino alkane compound~~derivatives lower~~ lowers the plasma glucose concentration in about 1 hr to 7 hrs during post drug administration.

Claim 56. (currently amended): A pharmaceutical composition for the treatment ~~or prevention~~ of cardiovascular disorders (CVS) and of hyperglycemic condition

(diabetes) in mammals, including humans, said composition comprising as the active ingredient, ~~an~~ a therapeutically effective dosage of an ω-naphthyloxy amino alkane ~~derivatives~~ compound having structural ~~Formula~~ formula I,



I

~~Wherein~~wherein, R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon ~~atomsselected~~ atoms selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl and hexyl; a branched chain lower alkyl selected from the group consisting of isopropyl, isobutyl and t-butyl; a cyclic alkane selected from the group consisting of cyclopropyl, cyclobutyl, cyclohexyl and cycloheptyl; a lower alkoxy in which the alkyl group is as mentioned above, n is 1 to 6; R_3 and R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined above; an aryl ~~residueselected~~ residue selected from the group consisting of phenyl~~, substituted phenyl~~ and naphthyl; an arylalkyl residue selected from the group consisting of benzyl and substituted benzyl, form a part of a ~~heterocylic~~ heterocyclic ring selected from the group consisting of pyrrolidine and piperidine, form a ~~heterocylic~~ heterocyclic ring with additional heteroatoms ~~O,N,S~~O, N, S selected from the group consisting of piperazine, morpholine, oxazole, ~~oxathinazole~~ oxathiazole and oxathiazine; an alkoxy carbonyl alkane represented by the formula R_6COOR_7, wherein R_6 is $(CH_2)n$ (n=1-3) and R_7 is a lower alkyl as defined above, optionally along with acceptable salt/s, carrier/s or ~~dilutent~~diluent/s, wherein the salts/carriers/diluents are selected from the group consisting of lactose, sodium chloride, potassium chloride, magnesium sulphate, magnesium chloride, potassium sulfate, sodium sulfate, lithium sulphate, sodium phosphate, potassium phosphate, magnesium succinate, sodium carbonate, sodium sulfate, potassium acid phosphate and calcium bicarbonate.

Claim 57. (canceled).

Claim 58. (currently amended): ~~A~~ The composition as claimed in claim 56, wherein**[[,]]** said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~are~~ is selected from the group consisting of:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]_amine [I:_R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl] amine_[I: R_1= R_2=H, R_3= propyl R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino**[[}]]** acetic acid ethyl ester [I: R_1=R_2=H, R_3= CH_2COOEt, R_4~~CH_2COOEt~~,R_4=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]_amine_[I:_R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)butylamine [I:_R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]_amine_[I:_R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:__R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]_amine_[I:_R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]_amine_[I:_R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine_[I:__R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]___amine___[I:___R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]__amine [I:__R_1=R_2=R_3=H,R_4= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:_R_1=R_2=R_3=H,R_4= benzyl, n=3] **[[]]]**

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]__amine__[I:__R_1=R_2=R_3=H,R_4= benzyl, n=4] **[[]]]**

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I: **[[:]]** R_1 = R_2 = R_3 = H, R_4 = ~~cylohexyl, n=2~~cyclohexyl, n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I: **[[:]]** R_1 = R_2 = R_3 =H, R_4 = ~~cylohexyl,n=3~~cyclohexyl, n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]__amine__[I:__R_1=R_2=R_3=H, R_4 = ~~cylohexyl,n=4~~cyclohexyl, n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]amine [I: **[[:]]** R_1 = R_2 = R_3 = ~~H,~~R_4H, R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine_[I:_R_1=R_2= R_3= H, R_4=2-ethyl- n-hexyl, n=3]**[[.]]**

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl]___amine___[I:___R_1=R_2=R_3=H, **[[,]]**R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]_amine [I:_R_1=R_2=R_3= ~~H,~~R_4H, R_4= ~~n-dodecyl,n=2~~n-dodecyl, n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:_R_1= R_2 = R_3 = H, R_4=~~n-dodecyl,n=3~~n- dodecyl, n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]_amine_[I:_R_1=R_2= R_3= H, R_4~~H,~~R_4= ~~n-dodecyl,n=4~~n-dodecyl, n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]_amine [I:_R_1=R_2 = R_3 = H, R_4~~H,~~R_4= isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]__amine__[I:__R_1=R_2=R_3=H, R_4 = isoamyl, n =3]

(xxviii) N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]_amine_[I: R_1 = R_2 = R_3 = H, **[[,]]** R_4 = ~~isoamyl,n=4~~isoamyl, n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:_R_1=R_2= R_3=H, **[[,]]** R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: $R_1=R_2=R_3=$ H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: $R_1=R_2=R_3$=H, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: $R_1=R_2=R_3$=H, R_4=n-octyl, n=2]

(xxxiii) N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]_amine [I: $R_1=R_2=R_3$=H, R_4=n-octyl, n=3]

(xxxiv) N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: $R_1=R_2=R_3$=H, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: $R_1=R_2=R_3$=H, R_4=n-butyl, n=4]

(xxxvi) N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: $R_1=R_2=R_3$=H, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I:**[[,]]** $R_1=R_2=R_3$=H, R_4=2-phenyl- ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I:**[[,]]** $R_1=R_2=R_3$=H, R_4= Piperidinyl, n=4]

(xxxix) N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** $R_1=R_2=$ $R_3=$ H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** $R_1=R_2=$ $R_3=$ H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]_amine [I:**[[,]]** R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propyl]_____amine**[[,]]** [I:**[[,]]** R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4 Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl] amine**[[.]]** [I:**[[,]]** R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl] amine__[I:**[[,]]** R_1=R_2=H, R_3= n-butyl, R_4=4-methoxyphenyl~~4-Methoxyphenyl~~, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino**[[}]]** acetic acid ethyl ester[I:**[[,]]** R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-methoxyphenyl~~4-Methoxyphenyl~~, n=3]

(xlviii) 2,7-Bis[3-(4-methoxyphenylamino)propyloxy]___naphthalene___[I:**[[,]]** R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

and

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]___naphthalene___[I:**[[,]]** R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl]**[[/]].**

Claim 59. (currently amended): ~~A~~ The composition as claimed in claim 56, wherein the dosage of the said ~~derivatives~~ ω-naphthyloxy amino alkane compound is in the range of about 250-350 μmol/Kg.

Claim 60. (currently amended): ~~A~~ The composition as claimed in claim 59, wherein the dosage of the said ~~derivatives~~ ω-naphthyloxy amino alkane compound is about 300 μmol/Kg.

Claim 61. (currently amended): ~~A~~ The composition as claimed in claim 56, ~~wherein the said derivatives may be administered~~ in the form of a syrup, a capsule, a tablet, a suspension or intravenous preparation.

Claim 62. (currently amended): ~~A~~ The composition as claimed in claim 56, wherein the method of administration ~~of said derivatives~~ is oral, nasal, or parenteral.

Claim 63. (currently amended): ~~A~~ The composition as claimed in claim 56, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound lowers ~~lower~~ ~~the~~ plasma concentration ~~percentage~~ of cholesterol by about 30%.

Claim 64. (currently amended): ~~A~~ The composition as claimed in claim 63, wherein said ω-naphthyloxy amino alkane compound~~derivatives~~ lowers ~~the~~ plasma concentration of cholesterol by about 26%.

Claim 65. (currently amended): ~~A~~ The composition as claimed in claim 56, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~lower~~lowers ~~the~~ plasma concentration of ~~phospholipid~~ phospholipids by about 35%.

Claim 66. (currently amended): ~~A~~ The composition as claimed in claim 65, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~lower~~lowers ~~the~~ plasma concentration of ~~phospholipid~~ phospholipids by about 30%.

Claim 67. (currently amended): ~~A~~ The composition as claimed in claim 56, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~lower~~ lowers ~~the~~ plasma concentration of ~~triglyceride~~ triglycerides by about 50%.

Claim 68. (currently amended): ~~A~~ The composition as claimed in claim 67, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~lower~~lowers ~~the~~ plasma concentration of ~~triglyceride~~ triglycerides by about 48%.

Claim 69. (currently amended): ~~A~~ The composition as claimed in claim 56, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~enhance~~enhances ~~the~~ plasma concentration of high-density lipoprotein (HDL) by about 20%.

Claim 70. (currently amended): ~~A~~ The composition as claimed in claim 69, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~enhance~~enhances ~~the~~ plasma concentration of high-density lipoprotein (HDL) ~~preferably~~ by about 15%.

Claim 71. (currently amended): ~~A~~ The composition as claimed in claim 56, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~lower~~lowers ~~the~~ plasma glucose (GLU) concentration by about 40%.

Claim 72. (currently amended): ~~A~~ The composition as claimed in claim 71, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~lower~~lowers ~~the~~ plasma glucose (GLU) concentration by about 30%.

Claim 73. (currently amended): ~~A~~ The composition as claimed in claim 56, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound lowers ~~the~~ plasma glycerol (GLY) concentration by about 20%.

Claim 74. (currently amended): ~~A~~ The composition as claimed in claim 73, wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound lowers ~~the~~ plasma glycerol concentration by about 14%.

Claim 75. (currently amended): ~~A~~ The composition as claimed in claim 56 wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~lower~~lowers ~~the~~ plasma glucose concentration in about 30 min to 10 hours ~~during~~ post ~~drug~~ administration.

Claim 76. (currently amended): ~~A~~ The composition as claimed in claim 75 wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~lower~~lowers ~~the~~ plasma glucose concentration in about 1 hr to 7 hrs ~~during~~ post ~~drug~~ administration.

Claim 77. (currently amended): A method for treatment ~~or prevention~~ of cardiovascular disorders and hyperglycemia (diabetes) ~~by~~ comprising administering a ~~pharmaceutically~~ composition comprising as an active ingredient, a therapeutically effective dosage of a ω-naphthyloxy amino alkane ~~derivatives~~ compound having structural ~~Formula~~ formula I,



II

~~Wherein~~ wherein R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon atoms, selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl and hexyl; a branched chain lower alkyl selected from the group consisting of isopropyl, isobutyl ~~and t-butyl~~and t-butyl; a cyclic alkane selected from the group consisting of cyclopropyl, cyclobutyl, cyclohexyl and cycloheptyl; a lower alkoxy in which the alkyl group is as mentioned above, n is 1 to 6; R_3 and

R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined above; an aryl residue selected from the group consisting of phenyl~~, substituted phenyl~~ and naphthyl; an arylalkyl residue selected from the group consisting of benzyl and substituted benzyl, form a part of a ~~heterocylic~~ heterocyclic ring selected from the group consisting of pyrrolidine and piperidine, form a ~~heterocylic~~ heterocyclic ring with additional heteroatoms ~~O,N,S~~O, N, S selected from the group consisting of piperazine, morpholine, oxazole, ~~oxathinazole~~ oxathiazole and oxathiazine; an alkoxy carbonyl alkane represented by the formula R_6COOR_7, wherein R_6 is $(CH_2)n$ (n=1-3) and R_7 is a lower alkyl as defined above, ~~optionally along with~~and acceptable salt/s, carrier/s or ~~dilutent~~diluent/s, wherein the salts/carriers/diluents are selected from the group consisting of lactose, sodium chloride, potassium chloride, magnesium sulphate, magnesium chloride, potassium sulfate, sodium sulfate, lithium sulphate, sodium phosphate, potassium phosphate, magnesium succinate, sodium carbonate, sodium sulfate, potassium acid phosphate and calcium bicarbonate.

Claim 78. (canceled).

Claim 79. (currently amended): A method as claimed in claim 77 wherein said ~~derivatives~~ ω-naphthyloxy amino alkane compound ~~are~~ is selected from the group consisting of:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]amine [I: $R_1=R_2=R_3=H$, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl] amine [I: $R_1=R_2=H$, R_3= propyl R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino**[[}]]** acetic acid ethyl ester [I: R_1=R_2=H, R_3= CH_2COOEt, R_4~~CH_2COOEt,R_4~~=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]_amine_[I:_R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)butylamine [I:_R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]_amine_[I:_R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:__R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]_amine_[I:_R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]_amine_[I:_R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine_[I:_R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]___amine___[I:___R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]_amine [I:_R_1=R_2=R_3=~~H,R_4~~H, R_4= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=3] **[[]]]**

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]__amine__[I:__R_1=R_2=R_3=H,R_4= benzyl, n=4] **[[]]]**

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]_amine_[I: **[[:]]** R_1 = R_2 = R_3 = H, R_4 = ~~cylohexyl~~cyclohexyl, n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I: **[[:]]** R_1 = R_2 = R_3 =H, R_4 = ~~cylohexyl,n=3~~cyclohexyl, n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]__amine__[I:__R_1=R_2=R_3=H, R_4 = ~~cylohexyl,n=4~~cyclohexyl, n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]_amine [I: **[[:]]** R_1 = R_2 = R_3 = ~~H,R_4~~H, R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine_[I:_R_1=R_2= R_3= H, R_4=2-ethyl- n-hexyl, n=3]**[[.]]**

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl] amine___[I:___R_1=R_2=R_3=H, **[[,]]**R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]_amine [I:_R_1=R_2=R_3= ~~H,R_4~~H, R_4= ~~n-dodecyl,n=2~~n-dodecyl, n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1= R_2 = R_3 = H, R_4=~~n-dodecyl,n=3~~n-dodecyl, n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]_amine_[I:_R_1=R_2= R_3= ~~H,R_4~~H, R_4= ~~n-dodecyl,n=4~~n-dodecyl, n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]_amine [I:_R_1=R_2 = R_3 = H, R_4~~H,R_4~~= isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]__amine__[I:__R_1=R_2=R_3=H, R_4 = isoamyl, n =3]

(xxviii) N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]_amine_[I: **[[:]]** R_1 = R_2 = R_3 = H, **[[,]]** R_4 = ~~isoamyl,n=4~~isoamyl, n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:_R_1=R_2= R_3=H, **[[,]]** R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1=R_2=R_3= H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=2]

(xxxiii) N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]_amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=3]

(xxxiv) N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-butyl, n=4]

(xxxvi) N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I:**[[,]]** R_1=R_2=R_3=H, R_4=2-phenyl- ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I:**[[,]]** R_1=R_2=R_3=H, R_4= Piperidinyl, n=4]

(xxxix) N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2= R_3= H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2= R_3= H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]_amine [I:**[[,]]** R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propyl]_amine, [I:**[[,]]** R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4-Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl] amine**[[.]]** [I:**[[,]]** R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl] amine [I:**[[,]]** R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl] amine [I:[[,]]R_1=R_2=H, R_3= n-butyl, R_4=4-methoxyphenyl~~4-Methoxyphenyl~~, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino[[}]] acetic acid ethyl ester[I:[[,]] R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-methoxyphenyl~~4-Methoxyphenyl~~, n=3]

(xlviii) 2,7-Bis[3-(4-methoxyphenylamino)propyloxy]___naphthalene___[I:[[,]] R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

and

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I:[[,]] R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl].

Claim 80. (currently amended): The~~A~~ method as claimed in claim 77, wherein the dosage of the ~~said derivatives~~ ω-naphthyloxy amino alkane compound is in the range of about 250-350 μmol/Kg.

Claim 81. (currently amended): ~~A~~ The method as claimed in claim 80, wherein the dosage of the ~~said derivatives~~ω-naphthyloxy amino alkane compound is about 300 μmol/Kg.

Claim 82. (currently amended): ~~A~~ The method as claimed in claim 77, wherein the ~~said derivatives may be~~composition is administered in form of a syrup, a capsule, a tablet, a suspension or ~~intravenous~~intravenously.

Claim 83. (currently amended): ~~A~~ The method as claimed in claim 77, wherein the method of administration of said ~~derivatives~~ composition is ~~oral~~oral, nasal, or parenteral.

Claim 84. (currently amended): ~~A~~ The method as claimed in claim 77, wherein ~~said derivatives lower the concentration percentage of~~ plasma cholesterol concentration is lowered by about 30%.

Claim 85. (currently amended): ~~A~~ The method as claimed in claim 84, wherein ~~said derivatives lowers the concentration of~~ plasma cholesterol concentration is lowered by about 26%.

Claim 86. (currently amended): ~~A~~ The method as claimed in claim 77, wherein ~~said derivatives lower the concentration of~~ plasma phospholipid concentration is lowered by about 35%.

Claim 87. (currently amended): The~~A~~ method as claimed in claim 86, wherein ~~said derivatives lower the concentration of~~ plasma phospholipid concentration is lowered by about 30%.

Claim 88. (currently amended): ~~A~~ The method as claimed in claim 77, wherein ~~said derivatives lower the concentration of~~ plasma triglyceride concentration is lowered by about 50%.

Claim 89. (currently amended): ~~A~~ The method as claimed in claim 88, wherein ~~said derivatives lower the concentration of~~ plasma triglyceride concentration is lowered by about 48%.

Claim 90. (currently amended): ~~A~~ The method as claimed in claim 77, wherein ~~said derivatives enhance the concentration of~~ plasma high-density lipoprotein (HDL) concentration is enhanced by about 20%.

Claim 91. (currently amended): ~~A~~ The method as claimed in claim 90, wherein ~~said derivatives enhance the concentration of~~ plasma high-density lipoprotein (HDL) concentration is enhanced by about 15%.

Claim 92. (currently amended): ~~A~~ The method as claimed in claim 77, wherein ~~said derivatives lower the~~ plasma glucose (GLU) concentration is lowered by about 40%.

Claim 93. (currently amended): ~~A~~ The method as claimed in claim 92, wherein ~~said derivatives lower the~~ plasma glucose (GLU) concentration is lowered by about 30%.

Claim 94. (currently amended): ~~A~~ The method as claimed in claim 77 wherein ~~said derivatives lower the~~ plasma glycerol (GLY) concentration is lowered by about 20%.

Claim 95. (currently amended): ~~A~~ The method as claimed in claim 94 wherein ~~said derivatives lower the~~ plasma glycerol concentration is lowered by about 14%.

Claim 96. (currently amended): The~~A~~ method as claimed in claim 77, wherein ~~said derivatives lower the~~ plasma glucose concentration is lowered in about 30 min to 10 hours ~~during~~ post ~~drug~~ administration of the composition.

Claim 97. (currently amended): ~~A~~ The method as claimed in claim 96, wherein ~~said derivatives lower the~~ plasma glucose concentration is lowered in about 1 hr to 7 hrs ~~during~~ post ~~drug~~ administration of the composition.